<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01215903</url>
  </required_header>
  <id_info>
    <org_study_id>SIRUL-85742</org_study_id>
    <nct_id>NCT01215903</nct_id>
  </id_info>
  <brief_title>Fish Gelatin Supplement and Omega-3 Supplement in Obese or Overweight Subjects With Insulin Resistance</brief_title>
  <official_title>The Beneficial Effects of Fish Nutrients on the Obesity-linked Metabolic Syndrome and Cardiovascular Risk Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advance Foods and Materials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut des Nutraceutiques et Aliments fonctionnels, Quebec (Clinical nutrition facilities)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Guelph</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ocean Nutrition Canada, Halifax (in-kind support: omega-3 supplements)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenney &amp; Ross Limited, Nova Scotia (in-kind support: Fish gelatin)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study was conducted to test whether a fish gelatin supplement combined with an
      omega-3 polyunsaturated fatty acid supplement can exert beneficial and sex-specific effects
      on insulin sensitivity, glucose tolerance, indicators of insulin secretion, blood pressure,
      lipid metabolism, inflammation and energy intake in obese or overweight insulin-resistant men
      and women. The investigators hypothesis is that fish gelatin improves insulin sensitivity,
      glucose tolerance, lipid profile and reduces inflammation in obese or overweight
      insulin-resistant men and women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An important number of recent epidemiological studies have demonstrated the beneficial
      effects of marine omega-3 polyunsaturated fatty acids (n-3 PUFA) on cardiovascular disease
      risk factors such as reduced triglycerides, decreased platelet aggregation, plaque
      stabilization, antiarrhythmic effects, and reduced blood pressure. Dietary fish protein has
      also been shown to improve insulin sensitivity by 30% in insulin-resistant obese or
      overweight human subjects. In addition, an increasing number of studies describe and
      demonstrate the physiological and metabolic variations between men and women in regard to CVD
      and their risk factors, including type 2 diabetes, but the data are still limited. In
      agreement with the recent findings, this study was conducted to evaluate the combined and
      synergistic effects of omega-3 and fish protein supplements on insulin sensitivity, blood
      pressure, lipid metabolism and inflammation in obese or overweight insulin-resistant men and
      women having some or all the metabolic syndrome criteria including a deteriorated lipid
      profile, high blood pressure and high waist circumference in a free living situation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>At 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma lipids and lipoproteins</measure>
    <time_frame>at 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>At 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and serum inflammatory markers</measure>
    <time_frame>At 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>At 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy intake</measure>
    <time_frame>At 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acids of phospholipids in skeletal muscle</measure>
    <time_frame>At 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Fish gelatin and omega-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish gelatin and omega-3 polyunsaturated fatty acid</intervention_name>
    <arm_group_label>Fish gelatin and omega-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 polyunsaturated fatty acid</intervention_name>
    <arm_group_label>Omega-3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  overweight or obese (body mass index [BMI] between 25 and 40kg/m2)

          -  fasting plasma glucose below 7.0mmol/L and 2-h plasma glucose below 11.1mmol/L

          -  fasting plasma insulin above 90pmol/L

        Exclusion Criteria:

          -  Diabetes, chronic, metabolic or acute disease

          -  Major surgery within the last 3 months

          -  Significant weight loss (Â±10%) within the last 6 months

          -  Any medication-taking known to affect lipid of glucose metabolism

          -  Allergy, intolerance or dislike of fish

          -  Smokers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helene Jacques, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andre Marette, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John S Weisnagel, MD/FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laval University</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>October 22, 2010</last_update_submitted>
  <last_update_submitted_qc>October 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2010</last_update_posted>
  <responsible_party>
    <name_title>Helene Jacques, PhD</name_title>
    <organization>Laval University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

